AROG4-01 / Aromics Therapeutics - LARVOL DELTA

First in human phase 1 dose escalation and expansion clinical trial to evaluate the safety, pharmacokinetics and antitumor activity of intravenous AROG4-01 in patients with advanced solid tumors. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT06652529 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P1 data • PK/PD data • Oncology • Solid Tumor

First in human phase 1 dose escalation and expansion clinical trial to evaluate the safety, pharmacokinetics and antitumor activity of intravenous AROG4-01 in patients with advanced solid tumors (AACR 2025) - P1 | "Three sites in Spain are expected to participate. Recruitment is not yet open."

Clinical • Metastases • P1 data • PK/PD data • Mesothelioma • Oncology • Solid Tumor